Wilbanks Smith & Thomas Asset Management LLC lowered its position in Allergan PLC. (NYSE:AGN) by 35.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,067 shares of the company’s stock after selling 588 shares during the quarter. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Allergan PLC. were worth $259,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of AGN. Howard Hughes Medical Institute purchased a new stake in Allergan PLC. in the second quarter worth approximately $103,000. Jacobi Capital Management LLC boosted its stake in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares in the last quarter. JNBA Financial Advisors boosted its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Massey Quick & Co. LLC boosted its stake in Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after buying an additional 385 shares in the last quarter. Finally, Pacific Center for Financial Services boosted its stake in Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares in the last quarter. 81.94% of the stock is owned by institutional investors and hedge funds.

Allergan PLC. (AGN) opened at 198.99 on Tuesday. The company has a market cap of $66.52 billion, a P/E ratio of 6.06 and a beta of 1.15. The firm has a 50-day moving average price of $215.75 and a 200-day moving average price of $231.93. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. Allergan PLC.’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $3.35 EPS. On average, equities research analysts forecast that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.

Allergan PLC. announced that its Board of Directors has authorized a share buyback plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/10/17/wilbanks-smith-thomas-asset-management-llc-cuts-holdings-in-allergan-plc-agn.html.

Several analysts have weighed in on AGN shares. Citigroup Inc. reiterated a “buy” rating and issued a $280.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 20th. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. Piper Jaffray Companies set a $227.00 price objective on Allergan PLC. and gave the company a “hold” rating in a research report on Friday, October 6th. Wells Fargo & Company set a $276.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research report on Friday. Finally, Cowen and Company reiterated an “outperform” rating and issued a $400.00 price objective on shares of Allergan PLC. in a research report on Saturday, September 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $268.74.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.